OPHTHALMOLOGY

Ocular Safety Signals of Fibroblast Growth Factor Receptor Inhibitors in Postmarketing Surveillance

Sep 20, 2026 by in OPHTHALMOLOGY Comments Off on Ocular Safety Signals of Fibroblast Growth Factor Receptor Inhibitors in Postmarketing Surveillance
Highlights • Erdafitinib demonstrated the broadest and strongest signals for corneal and retinal toxicity. • Pemigatinib was predominantly associated with retinal fluid disorders and serous detachments. • Findings align with…
read more

Reply to Comment on: Interferon alpha-2a as treatment for primary acquired melanosis with atypia and for primary acquired melanosis with atypia surrounding conjunctival melanoma

Sep 20, 2026 by in OPHTHALMOLOGY Comments Off on Reply to Comment on: Interferon alpha-2a as treatment for primary acquired melanosis with atypia and for primary acquired melanosis with atypia surrounding conjunctival melanoma
W e would like to thank Yadav, Yadav, and Rastogi for highlighting the strengths of our study, which showed a lasting complete response when treating conjunctival primary acquired melanosis (PAM)…
read more

Risk of Retinal Detachment After Intravitreal Injection of Anti-VEGF: A Systematic Review and Meta-Analysis

Sep 20, 2026 by in OPHTHALMOLOGY Comments Off on Risk of Retinal Detachment After Intravitreal Injection of Anti-VEGF: A Systematic Review and Meta-Analysis
Topic This systematic review and meta-analysis evaluated the literature-pooled risk of retinal detachment (RD) following intravitreal injection (IVI) of anti–vascular endothelial growth factor (anti-VEGF) agents. Clinical Relevance Intravitreal anti-VEGF injections…
read more

Immune Checkpoint Inhibitor–Associated Uveitis: Insights From Comparative Analyses Across Malignancies and Drug Classes

Sep 20, 2026 by in OPHTHALMOLOGY Comments Off on Immune Checkpoint Inhibitor–Associated Uveitis: Insights From Comparative Analyses Across Malignancies and Drug Classes
Highlights • Melanoma patients face the highest risk of checkpoint inhibitor–associated uveitis. • Ipilimumab/nivolumab exposure accounts for part, but not all, of the increased risk. • Anterior uveitis was the…
read more

Ocular Hypertension Treatment Study: Effect of Time After Incident Glaucoma on OCT Optic Nerve Head and Macula Measurements

Sep 20, 2026 by in OPHTHALMOLOGY Comments Off on Ocular Hypertension Treatment Study: Effect of Time After Incident Glaucoma on OCT Optic Nerve Head and Macula Measurements
Purpose The objectives of this report are to compare optical coherence tomography (OCT) based retinal nerve fiber layer (RNFL) and ganglion cell/ inner plexiform layer (GCIPL) thickness in participants who…
read more

Predictors of 1-Year Visual Outcome in Central-Involving Submacular Hemorrhage Secondary to Neovascular AMD

Sep 20, 2026 by in OPHTHALMOLOGY Comments Off on Predictors of 1-Year Visual Outcome in Central-Involving Submacular Hemorrhage Secondary to Neovascular AMD
Highlights • One-third of eyes with acute SMH retained driving-level vision at 12 months. • Subfoveal choroidal thickness independently predicted visual recovery. • Larger hemorrhage size and diabetes mellitus predicted…
read more
Get Clinical Tree app for offline access